The literature confirms the functional efficacy of core features like DNR in improving the SNR and auditory comfort (Deniz et al., 2024) [7] , and it has begun to explore these benefits using rigorous neurophysiological metrics like cABR (Hossain et al., 2024) [14] . However, the evidence is divided on the value of premium technology tiers, with independent research suggesting clinical equivalence between basic and premium devices in daily life outcomes (Cox et al., 2014; Cox et al., 2017) [9] [15] . This indicates that the core technological benefits may be widely distributed across all tiers. Finally, the role of auditory training (Hanin & Hanin, 2022) [13] is established as a necessary, complementary strategy to optimize the brain’s processing capacity alongside the use of HAs.

The review of related literature reveals a critical gap between the demonstrated efficacy of individual digital features and the clinical justification for tiered hearing aid technology. While studies confirm that basic features like Digital Noise Reduction (Deniz et al., 2024) [7] and directional processing (Cox et al., 2014) [9] provide measurable benefits, independent research consistently reports that premium-level devices offer essentially equivalent daily-life outcomes compared to basic-feature models (Cox et al., 2014; Cox et al., 2017) [9] [15] .

This stark contradiction between market segmentation and objective, evidence-based results create a significant deficiency in clinical guidance, leaving audiologists without sufficient data to make evidence-based recommendations regarding the cost-benefit ratio of high-tier technology.

A further need exists in objectively validating the impact of feature integration. Although neurophysiological tools like cABR have been introduced to explore the effect of simple noise reduction (Hossain et al., 2024) [14] , a comprehensive, objective analysis linking complex, integrated feature sets across different technology tiers to neurophysiological markers of auditory clarity and reduced cognitive load remains underdeveloped. The field requires research that moves beyond self-report measures and behavioral scores to provide the granular, objective data necessary to justify or refute the premium pricing structure.

By rigorously investigating the incremental benefit of advanced features in ecologically valid conditions, this study aims to resolve the current clinical ambiguity and ensure that patient recommendations align with validated scientific benefit.

The primary aim of this study is to provide the objective, evidence-based data necessary to resolve the ambiguity surrounding the clinical value and cost-effectiveness of tiered hearing aid technology. Specifically, the research aims to:

Quantify Incremental Behavioral Benefit: Determine if complex, integrated feature sets present in premium hearing aids offer a statistically significant and clinically relevant improvement in speech understanding and reduced listening effort compared to basic-feature hearing aids when assessed in ecologically valid, multi-talker noise environments.

Objectively Validate Feature Impact: Utilize neurophysiological measures, specifically the complex Auditory Brainstem Response (cABR), to objectively validate the impact of advanced digital signal processing (DSP) algorithms across technology tiers on the neural encoding of speech and central auditory clarity.

Inform Clinical Practice: Bridge the gap between manufacturer claims and independent research findings to provide audiologists with clear, objective evidence for making cost-benefit recommendations regarding hearing aid technology tiers.

The selection of academic literature and research reports for this thesis was governed by stringent criteria to ensure maximum relevance and validity for addressing the stated aims. The literature search was confined to documents available in the English language and published within the last ten years (2014 to present) to ensure technological relevance, though foundational historical studies were considered if essential.

All included studies had to demonstrate Subject Matter Relevance, specifically focusing on the clinical and functional outcomes of digital hearing aid signal processing features, such as Digital Noise Reduction (DNR), directional microphone technology (beamforming), Deep Neural Network (DNN) processing, and integrated feature sets.

A prerequisite for inclusion was a Comparative Analysis, meaning the research involved a direct comparison between different technology levels (e.g., premium vs. basic, feature “on” vs. “off” conditions) or compared aided performance to unaided performance.

Furthermore, studies were required to incorporate Objective Outcome Measures, encompassing both Behavioral Measures (Speech recognition in noise, listening effort) and/or Physiological Measures (Neurophysiological responses like cABR, EEG, or cognitive load proxies).

Finally, all documents were filtered for Publication Quality, restricted to peer-reviewed journal articles, published field studies, or authoritative insight reports from major hearing aid manufacturers, and the Population Focus was limited to adult or older adult participants with sensorineural hearing loss.

To maintain the methodological focus and avoid confounding variables, any scholarly work that met the following conditions was excluded from this review. This included studies focused solely on pediatric populations (children or adolescents) or animal models, as their audiological needs and central processing are distinct from the target adult population. Any literature that did not utilize a digital hearing aid device (e.g., studies examining only analog devices or cochlear implants without comparison to digital HAs) was disqualified. Furthermore, research that relied exclusively on unvalidated subjective self-report questionnaires without incorporating a complementary objective or standardized behavioral outcome measure (such as speech-in-noise testing or cABR) was excluded.

Finally, articles published prior to 2014 were systematically excluded, apart from seminal works cited within the included contemporary literature, to ensure that the findings reflect the performance of current digital signal processing technology.

To ensure that the literature synthesis accurately reflects the most robust evidence, a critical appraisal of the included comparative and neurophysiological studies was conducted, focusing on three key domains relevant to audiology research to identify potential risks of bias. First, Trial Design was assessed: preference was given to studies employing double-blind, randomized crossover designs, as these minimize participant and assessor bias, particularly for subjective measures like listening effort; studies with non-randomized or non-crossover designs were noted as having a higher potential for sequence and carryover effects. Second, Outcome Measures and Blinding were scrutinized: studies relying solely on self-report were deemed less robust than those incorporating objective measures, such as validated speech-in-noise tests and neurophysiological outcomes (e.g., ABR or pupillometry), with a lack of blinding of the outcome assessor considered a significant source of performance bias. Finally, Statistical Power and Sample Size were considered, meaning studies with small sample sizes (N < 20) or those lacking reported power calculations were weighted less heavily in the synthesis of primary findings. This formal appraisal guided the subsequent narrative, ensuring that findings from high-quality, randomized crossover trials with objective outcomes were given greater weight than those derived from observational or non-blinded comparisons in drawing definitive conclusions regarding the efficacy of hearing aid technologies.

While the review prioritizes high-quality comparative studies, it acknowledges that the evidence base, particularly for advanced features like wireless remote microphone (RM) systems, often features manufacturer-sponsored research, which may introduce publication or reporting bias. To ensure a balanced synthesis, this review critically weights the findings from these reports against independent, peer-reviewed Randomized Controlled Trials (RCTs). For instance, the significant and consistent speech perception benefits demonstrated by RM systems in real-world simulations are powerfully corroborated by independent studies, such as the comprehensive RCT by Johnson et al. (2020) [16] , who found substantial improvements in speech recognition in challenging signal-to-noise ratios across different RM brands, irrespective of the core hearing aid technology tier. This approach allows the review to differentiate between consistent clinical efficacy and potentially biased promotional claims, thereby enhancing the reliability of the overall conclusions regarding the clinical value proposition of multi-modal solutions.

The systematic review followed a meticulous procedure to ensure comprehensive coverage and adherence to the defined Inclusion and Exclusion Criteria. The initial search was conducted across major academic databases, including PubMed/MEDLINE, Web of Science, and PsycINFO, utilizing key search terms such as: “hearing aid technology tiers,” “premium vs. basic hearing aids,” “digital noise reduction efficacy,” “cABR hearing aid,” and “listening effort hearing aid.” This broad search was designed to capture all potentially relevant literature published between 2014 and the present.

Subsequently, a two-stage screening process was implemented. The first stage involved screening the titles and abstracts generated by the initial search against the Inclusion and Exclusion Criteria for immediate relevance to digital signal processing and comparative design. Studies deemed relevant moved to the second stage, where the full-text articles were retrieved and critically reviewed. During the full-text review, each article was systematically evaluated to ensure it met all specified criteria—including the use of objective outcome measures, focus on adult/older adult populations, and proper comparative analysis.

A hand-search of the reference lists of all included full-text articles was also performed to identify any high-impact or foundational studies that may have been missed by the initial database search. All studies retained after the second screening constituted the final body of literature for synthesis in this thesis.

The systematic review process, while adhering to the defined Inclusion and Exclusion Criteria, did not follow all formal reporting guidelines for a quantitative systematic review. Specifically, the precise number of records identified, screened, or excluded is not formally reported, and a PRISMA-style flow diagram is not provided. Furthermore, the synthesis of the included literature relied on a narrative and thematic approach to aggregate findings and draw conclusions regarding functional equivalence and feature efficacy. Consequently, a formal, quantitative integration, which includes a standardized assessment of individual study quality or heterogeneity (e.g., risk of bias assessment), was not conducted, and the results reflect a synthesis of reported outcomes from the selected body of evidence.

The systematic review of the literature yielded synthesized findings directly addressing the three primary aims of this study, revealing a crucial functional and cognitive dichotomy regarding technology tiers. The majority of evidence comparing hearing aid technology tiers demonstrated a lack of incremental benefit for premium devices in daily-life behavioral functional outcomes. Specifically, multiple controlled crossover trials confirmed that both basic- and premium-level hearing aids provide substantial and clinically equivalent improvements in general speech understanding and self-reported quality of life for older adults with mild-to-moderate sensorineural hearing loss. However, this functional equivalence is contrasted by objective data demonstrating that advanced digital signal processing (DSP) features inherent in premium tiers effectively reduce the user’s cognitive load or mental fatigue, offering a scientifically validated benefit for those prioritizing listening with less effort. This finding necessitates a nuanced clinical recommendation based on the differential impact on cognitive metrics rather than just behavioral scores.

Crucially, no statistically significant differences were consistently found between the two technology tiers in these real-world functional domains.

A narrow, feature-specific advantage for premium devices was documented as reduced subjective listening effort, but this benefit was consistently limited to highly controlled, loud laboratory conditions and was often manufacturer-dependent (Cox et al., 2017) [15] . Conversely, the literature confirmed that individual digital signal processing (DSP) features do provide measurable, positive behavioral changes. For instance, Digital Noise Reduction (DNR) was found to effectively improve speech intelligibility in continuous noise and enhance auditory comfort (Deniz et al., 2024) [7] .

Furthermore, advanced directional beamforming configurations and features like Speech Enhancer were shown to significantly reduce listening effort (e.g., up to 29% for distant speech) and improve speech understanding in challenging listening environments (Latzel et al., 2024; Latzel et al., 2023) [19] [20] .

Addressing Aim 2, the review identified a growing body of work using physiological measures to objectively validate feature efficacy. Research utilizing the complex Auditory Brainstem Response (cABR) established a neurophysiological correlate for noise reduction effectiveness, demonstrating that noise degrades the neural coding of speech pitch (F0) (Hossain et al., 2024) [14] .

This indicates that the cABR is a viable objective tool for tracking how Digital Signal Processing (DSP) algorithms preserve central auditory clarity. Furthermore, studies specifically investigated the impact of advanced noise reduction on cognitive function while listening in noise (Huang et al., 2025; Crowhen et al., 2022) [4] [21] .

These results showed that features such as Spheric Speech Clarity significantly improved interference control and working memory capacity when compared to deactivated conditions, suggesting that these advanced processing features actively reduce the cognitive load or mental fatigue required to process complex auditory signals.

This supports the strong clinical recommendation for structured auditory training as an effective complementary intervention to accelerate the overall adaptation process (Hanin & Hanin, 2022) [13] .

The most salient finding addresses Aim 1—the quantification of incremental behavioral benefit—by reinforcing the independence of clinical success from technology tier. Consistent findings from multiple controlled crossover trials (Cox et al., 2014; Cox et al., 2017) [9] [15] demonstrated that the substantial, clinically relevant improvements in speech understanding and quality of life are equally achieved by both basic- and premium-level hearing aids.

This result strongly suggests that the cost difference between tiers is not reflected in widespread, statistically significant advantages for the end-user in daily-life listening environments. The marginal superiority of premium devices, which was documented only as reduced listening effort in highly specific, loud, and controlled laboratory conditions (Cox et al., 2017) [15] , fails to provide robust evidence to justify the significant price differential in standard clinical counseling. This collective evidence implies that the quality of the audiological fitting, programming, and patient orientation may be a greater determinant of success than the feature set complexity alone.

Conversely, the measurable benefits of core features like Digital Noise Reduction (DNR) (Deniz et al., 2024) [7] and advanced directional beamforming (Latzel et al., 2024) [19] are undeniable and represent the true minimum standard of modern amplification.

Addressing Aim 2, the literature demonstrates a critical shift toward objective validation. The integration of neurophysiological measures, such as the complex Auditory Brainstem Response (cABR) (Hossain et al., 2024) [14] , and cognitive metrics (Huang et al., 2025; Crowhen et al., 2022) [4] [21] , is highly significant. These studies provide the missing link between the activation of advanced DSP features and an observable, non-behavioral impact on the central auditory system.

Specifically, the ability to track the neural coding of speech pitch via cABR and document improved working memory and interference control through cognitive testing (Huang et al., 2025) [21] suggests that premium features may be effective at reducing cognitive load or mental fatigue, even if the patient’s resulting speech recognition score is saturated or unchanged. This reduced effort, though difficult to consistently measure behaviorally in real-world settings, represents a crucial, albeit subtle, benefit of high-tier technology.

The collective evidence from these objective measures provides a more robust, scientifically grounded pathway for differentiating technology tiers than behavioral tests alone.

The synthesized findings offer clear guidance for clinical practice (Aim 3). Audiologists should counsel patients based on evidence of functional equivalence in core speech understanding. Recommendations should emphasize the guaranteed benefits of core features and the strong clinical recommendation for complementary rehabilitative strategies like structured auditory training (Hanin & Hanin, 2022) [13] , which has demonstrated significant improvements in self-assessed ability and perceptual performance, particularly for new users.

A primary limitation of the current body of literature is the heavy reliance on data generated from manufacturer-sponsored field studies, particularly concerning the newest Deep Neural Network (DNN) features (Huang et al., 2025; Latzel et al., 2024) [19] [21] . While providing valuable objective insights, the lack of independent, multi-center replication remains a systemic limitation to drawing fully generalizable conclusions about the cost-benefit ratio. Furthermore, most studies are short-term; the long-term impact of consistently reduced cognitive load (the potential neuroprotective benefit of premium DSP) on overall cognitive decline in older adults remains an important unaddressed area.

Future research should prioritize independent, blinded, controlled trials that focus specifically on replicating the neurophysiological and cognitive benefits of integrated premium DSP features across different manufacturers. These studies must move beyond proprietary metrics and use standardized objective measures (cABR, cognitive load tests) in ecologically valid, multi-talker environments to finally provide the granular, objective data needed to definitively confirm or refute the widespread clinical justification for current hearing aid technology tiering.